44 results about "Theophylline" patented technology

The invention discloses a construction method of a cyanobacteria-corynebacterium glutamicum artificial photosynthetic mixed bacteria system. The construction method comprises the following steps: step S1, amplifying by taking plasmid pUC-tho as a template to obtain a theophylline inducible promoter Ptho; step S2, carrying out amplification by taking a Synechocystis sp. PCC 6803 genome as a template so as to obtain a strong promoter Pcpc560, and carrying out amplification on the strong promoter Pcpc560 so as to obtain a strong promoter Pcpc560; step S3, carrying out amplification by taking the plasmid pUC-PAL as a template to obtain an arabidopsis thaliana phenylalanine lyase gene pal; step S4, carrying out amplification by taking the plasmid pUC-cscB as a template to obtain an escherichia coli W sucrose transporter gene cscB; step S5, carrying out amplification by taking the integrated plasmid Pcp3031 as a template, so as to obtain a terminator Trbcl; and step S6, fusing the strong promoter Pcpc560, the arabidopsis phenylalanine lyase gene pal and the terminator Trbcl, and respectively connecting with an expression vector pSI-SPE to obtain the expression vector containing the gene pal. According to the invention, a'cyanobacteria-corynebacterium glutamicum 'artificial photosynthetic mixed bacteria system is constructed by simulating a mutualistic symbiotic relationship ubiquitous in nature, and negative carbon biosynthesis of cis-muconic acid is realized.

The invention belongs to the technical field of medicine detection, and particularly relates to an ICPMS (Inductively Coupled Plasma Mass Spectrometry) detection method for element impurities in theophylline. The linear test solution, the blank solution and the theophylline test solution are subjected to ICPMS detection, the content of element impurities in the theophylline test solution is calculated according to an internal standard curve method, and the element impurities are one or more of cadmium, lead, arsenic, mercury, cobalt, vanadium, nickel, lithium, antimony or copper. The method is good in reproducibility and stability, high in accuracy and high in precision.

The invention provides an ionic liquid antibacterial disinfectant, belongs to the technical field of medical preparations, and aims to solve the technical problem that chemical disinfectants are harmful to human bodies. The ionic liquid antibacterial disinfectant comprises an ionic liquid and deionized water, the proportion of the ionic liquid is 0.01%-100% by weight, and the proportion of the deionized water is 0%-99.99% by weight. The cation of the ionic liquid is imidazole, amine, piperidine or pyridine, and the anion of the ionic liquid is theophylline salt, mandelate, chlorine salt or dicyanide salt. The ionic liquid antibacterial disinfectant provided by the invention has a good sterilization effect, belongs to a novel antibacterial disinfectant which is non-volatile, non-irritant, healthy and environment-friendly, and has the characteristics of wide application scene, excellent sterilization effect, long antibacterial action time and environment friendliness.

The invention discloses allosteric DNA ribozyme and application thereof. The nucleotide sequence of the allosteric DNA ribozyme is selected from SEQ ID NO.01 to SEQ ID NO.10. The invention further discloses a preparation method of the allosteric DNA ribozyme The allosteric DNA ribozyme provided by the invention adopts a DNA structure, and compared with RNA ribozyme, the allosteric DNA ribozyme has higher chemical stability, is not easily degraded by nuclease, can complete theophylline detection within 60 minutes, does not need complex pretreatment or expensive instruments, is simple and convenient to operate, is suitable for bedside detection and household monitoring scenes, and greatly improves the detection efficiency.

The present application provides a composition with lipid-lowering and weight-reducing functions, which has clear components and controllable quality. The composition comprises Pu'er tea extract, wherein the Pu'er tea extract contains 10-90% theabrownine by weight, preferably also contains theophylline, the weight ratio of the theabrownine and theophylline is 10:1-60:1, and contains 0-15% tea polyphenols by weight. The theophylline can be selected from exogenous theophylline or theophylline contained in the Pu'er tea extract. The composition with lipid-lowering and weight-reducing functions of the present application also comprises Poria cocos extract; the weight ratio of the Pu'er tea extract to the Poria cocos extract is 1:3-3:1 based on the weight of theabrownine contained in the Pu'er tea extract. The composition of the present application has the advantages of clear effective components, simple preparation process, controllable quality, and stable lipid-lowering and weight-reducing effects.

The invention provides a preparation method of a choltheophylline bulk drug with high yield and high purity. The method mainly comprises the following steps: firstly, dissolving theophylline in a first solvent, adding trimethylamine after cooling treatment, and carrying out heat preservation and stirring at a certain temperature; then adding a base catalyst, cooling again, then adding chloroethanol, continuously stirring and slowly heating; filtering while the solution is hot, slowly cooling filtrate, adding a second solvent for crystallization, and filtering to obtain a crude cholintheophylline product; and then, dissolving the crude cholintheophylline in a third solvent, heating and stirring for a period of time, filtering while hot, cooling filtrate for crystallization, and finally, carrying out suction filtration and vacuum drying to obtain a cholintheophylline finished product. The choltheophylline bulk drug prepared by the method has excellent yield and purity, and is suitable for industrial production.

The invention relates to a theophylline immunodetection reagent as well as a preparation method and a detection method thereof, in particular to a theophylline chemiluminescence immunodetection reagent as well as a preparation method and a detection method thereof, and the theophylline chemiluminescence immunodetection reagent comprises an anti-theophylline specific antibody and an indicating reagent for detecting an anti-theophylline specific antibody-theophylline conjugate, the anti-theophylline specific antibody is obtained by immunizing animals with theophylline immunogen. The theophylline immunogen has the beneficial effects that the theophylline immunogen has strong specificity and high immunogenicity, and the prepared anti-theophylline specific antibody has strong specificity and high titer; the chemiluminescence immunoassay reagent containing the anti-theophylline specific antibody can conveniently, rapidly and accurately determine the theophylline content in a sample, can simultaneously determine a plurality of samples on a full-automatic chemiluminescence immunoassay instrument, realizes high-flux rapid determination of theophylline, and has the advantages of high accuracy, strong specificity, high sensitivity and high sensitivity. And the accuracy and the detection efficiency are greatly improved.

This invention belongs to the field of photoelectrochemical detection, specifically relating to a method for fabricating a photo-assisted all-solid-state zinc-air battery self-powered sensor based on a signal reversal strategy and its application in detecting theophylline. Using CuInS2 as the photocathode, CdS is loaded onto the photocathode using a split aptamer technique. Polished zinc foil is used as the anode, and PVA gel polymer is used as the solid electrolyte to construct a photo-assisted all-solid-state zinc-air battery self-powered sensor based on a signal reversal strategy. This invention achieves signal reversal by incorporating split aptamer technology, thereby significantly improving the detection sensitivity for antioxidants. The constructed photo-assisted all-solid-state zinc-air battery self-powered sensor based on a signal reversal strategy also has a wide detection range, low detection limit, and low detection cost.

The present invention provides an industrial method for synthesizing bitter theophylline with high purity and high quality.

The invention provides a method for rapidly detecting the content of theophylline in plasma, urine, medical sewage and functional beverages. According to the method, aiming at theophylline analytes in different samples, firstly, the samples are pretreated by adopting a liquid phase microextraction (LPME) technology, and then the pretreated theophylline is detected by adopting liquid phase-tandem mass spectrometry (LC-MS / MS). According to the method, an external standard method is adopted for quantification, the established method is good in linearity, the linear range is 0.01-10 mg / L, the correlation coefficient of theophylline is larger than 0.999, the detection limit is 0.2 microgram / L, the quantification limit is 0.7 microgram / L, the adding standard recovery rate is 86.7%-111.3%, and the relative standard deviation is smaller than 9%. The method is easy to operate and convenient to use, has the advantages of being good in accuracy, high in precision and sensitivity and the like, and provides a reliable method for rapid detection of theophylline in various actual scenes such as medical treatment, market supervision and environment monitoring.

The invention relates to the technical field of medicines, in particular to application of an adenosine A2A receptor antagonist in preparation of a medicine or food for preventing oxygen poisoning of a central nervous system. The invention provides a new application of an adenosine A2A receptor antagonist istradefylline. Animal experiments prove that the adenosine A2A receptor antagonist istradefylline can effectively delay the oxygen poisoning phenomenon of a central nervous system. Compared with the traditional method for preventing oxygen only by strictly limiting the pressure and time of oxygen inhalation, the method provided by the invention can be used for inhaling oxygen for a longer time under higher pressure, so that the application of hyperbaric oxygen in diving and hyperbaric medicine is further expanded.

The invention belongs to the technical field of molecular biology, and particularly discloses a theophylline aptamer and a virtual screening method and application thereof. The theophylline aptamer is selected from one or more of MUT9, MUT16, MUT67, MUT78 or MUT89. The invention further discloses a preparation method of the theophylline aptamer. The invention discloses a theophylline aptamer as well as a virtual screening method and application thereof, the theophylline aptamer is high in affinity and specificity, the virtual screening method remarkably improves the accuracy and efficiency of virtual screening, the theophylline aptamer can be quickly obtained at low cost, and a powerful calculation tool is provided for rational design and application of the aptamer.

The invention relates to a preparation method of a caffeine impurity C. The preparation method of the caffeine impurity C can effectively solve the problems of preparation of the caffeine impurity C, effective control of impurity content in caffeine and guarantee of coffee quality, and the preparation method comprises the following steps: mixing theophylline, a catalyst triethylene diamine, N, N-dimethylformamide and dimethyl carbonate, heating for reaction, distilling, adding water for recrystallization, and filtering to obtain the caffeine impurity C. Recrystallized jellyfish liquid is obtained; and adding a halogenated hydrocarbon solvent, standing until a solid is separated out between the water layer and the halogenated hydrocarbon solvent layer, filtering, and drying to obtain the product. The invention provides the caffeine impurity preparation method which is simple and easy to implement, mild in condition and low in energy consumption and pollution, so that the preparation vacancy of the impurity at present is filled up, powerful technical support is provided for quality research and quality control of caffeine, and the method has practical popularization and application values.

The invention discloses an N-aryl nuciferine derivative and a preparation method and application thereof.The chemical structure of the N-aryl nuciferine derivative is shown in the formula I. In the formula I, an aromatic ring A is selected from a benzene ring, a naphthalene ring, biphenyl or nitrogen heteroaromatic ring; r is selected from an electron-donating group and an electron-withdrawing group, or two ends of R are connected with an aromatic ring A to form a ring, the substitution number of the electron-donating group is 1-2, and the substitution number of the electron-withdrawing group is 1. The N-arylated nuciferine derivative disclosed by the invention has anti-lipase activity superior to that of a parent compound, can inhibit lipid accumulation in a cell differentiation process, and has further development potential.

The present invention relates to an anti-inflammatory extract of soil microorganisms or a fraction thereof, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria. The invention further relates to compositions comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS. The invention further relates to pharmaceutical compositions comprising the anti-inflammatory extract of soil microorganisms or a fraction thereof or a composition comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS as an active ingredient. The invention further relates to an anti-inflammatory extract of soil microorganisms or a fraction thereof or a pharmaceutical composition comprising an anti-inflammatory extract of soil microorganisms or a fraction thereof or a composition comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS as an active ingredient for use as a medicament, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria. The invention further relates to compositions comprising an anti-inflammatory extract of soil microorganisms or a fraction thereof, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria.

The invention discloses an electroplated copper foil electroplating liquid leveling agent with a crystal face guiding effect, and the leveling agent is thiamine, N-ethyl ethylenediamine, glycine, N, N-bis (2-ethoxyl) glycine, hexamethylphosphoramide, theophylline, 3-cyanopyridine, 2-hydroxypyridine, beta-methylpyridine, 1-(2-mercaptobenzothiazole-3-yl) imidazole, 1, 2-diphenyl-1, 3-pentanediol, 1, 3-pentanediol, 1, 3-pentanediol, 1, 3-pentanediol, 1, 3-pentanediol, 1, 3-pentanediol, 1, 3-pentanediol, 1, 3-pentanediol, 1, 3-pentanediol, 1, 3-pentanediol, 1, 3-pentanediol and 1, 3-pentanediol. The catalyst is selected from one or more of 1, 3-bis (1-imidazolyl) propane, 2-amino-4-methylbenzothiazole and pyridinium propanesulfonate. The leveling agent disclosed by the invention can homogenize grain size distribution on the surface of the electroplated copper foil and reduce a wrinkle phenomenon caused by microstress in a post-treatment process of the copper foil; meanwhile, the material can be adsorbed on the surface of the copper foil, copper ion nucleation overpotential is increased, deposited grains are refined, and the tensile strength of the copper foil is improved.

The invention discloses a method for simultaneously sensing and detecting two components of theophylline / caffeine based on a derived carbon-based material, the detection linear ranges of theophylline and caffeine are respectively 20-500 [mu] mol / L and 10-500 [mu] mol / L, the detection limits are respectively as low as 0.017 [mu] M and 0.021 [mu] M, and the sensitivities are respectively as high as 19.97 [mu] A / mM and 11.39 [mu] A / mM. Moreover, the sensor has the characteristics of high selectivity, good reproducibility, good stability and the like when being used for simultaneously detecting the theophylline and the caffeine, and is successfully used for simultaneously detecting the theophylline and the caffeine in the health-care food weight-reducing tea. It is worthy of mentioning that the nano material is easy and convenient to prepare and operate and short in consumed time, meanwhile, the nano material has the advantages of being low in raw material cost, wide and easy to obtain and the like, waste is turned into wealth, and the concept of sustainable development and green environmental protection is met.

The invention discloses a theophylline alkaloid salt, a pharmaceutical composition thereof, a preparation method of the theophylline alkaloid salt, and an application of the theophylline alkaloid salt, and belongs to the technical field of pharmaceutical chemistry. Natural alkaloids with definite pharmacological activity, such as stachydrine, betaine, trigonelline, sophocarpidine, choline or berberine, are selected as saline-forming bases, and a series of novel theophylline alkaloid salts are developed. The functional salt formation strategy not only fundamentally changes the traditional theophylline salt formation mode, but also realizes a leap-through breakthrough from single improvement of solubility to synergistic interaction and active attenuation. Through inherent gastric mucosa protection, heart function regulation and other effects of alkaloid, an active attenuation mechanism is constructed, the core toxic and side effects of gastrointestinal irritation, heart excitability and the like caused by theophylline are effectively reduced, the risk of introduction of exogenous sensitizers is avoided, and the bioavailability of theophylline is improved. The clinical problems of narrow therapeutic window and large toxic and side effects of traditional theophylline and salt drugs thereof are effectively solved.

A pharmaceutical composition in the form of a transdermal patch comprising aminophylline or theophylline for use in the treatment or prevention of a hypomyelinating or a demyelinating disease or condition or a lesion of the peripheral or central nervous system where demyelination occurs. The patch may comprise a matrix layer comprising a matrix polymer, an active ingredient and a permeation enhancer.

The invention discloses a preparation method of a theophylline controlled-release tablet and the theophylline controlled-release tablet. The preparation method comprises the following steps: S1, dry granulation of a medicine layer: preparing medicine layer particles from theophylline, a slow-release hydrophilic polymer material, a moisture absorbent, a flow aid and a lubricant; s2, performing dry granulation on the boosting layer: preparing boosting layer particles from a coloring material, an expansive high polymer material, a moisture absorbent, a flow aid and a lubricant; s3, tabletting of double-layer tablets: adding the medicine layer particles and the boosting layer particles into a double-layer tablet press for tabletting; s4, semi-permeable membrane coating: adding the theophylline double-layer tablet chip and a semi-permeable membrane coating solution into a coating machine; and S5, laser drilling: drilling holes in the theophylline double-layer semi-permeable membrane coating tablets through a laser drilling machine. The osmotic pump controlled release technology is utilized to control the constant-speed release of the medicine, the medicine effect is more lasting, the plasma concentration is stable, the adverse reaction of the medicine is effectively reduced, the medicine taking frequency is reduced, the medicine taking compliance of a patient is improved, and the clinical treatment effect of the medicine is improved.

The present invention provides methods for producing crystalline anti-PD-1 monoclonal antibodies (mAbs), wherein the mAbs are pembrolizumab or pembrolizumab variants, comprising (1) mixing a solution comprising (a) a mAb, (b) polyethylene glycol (PEG), and (c) an additive selected from the group consisting of caffeine, theophylline, 2'-deoxyguanosine-5'-monophosphate, a biologically active gibberellin, and a pharmaceutically acceptable salt of the biologically active gibberellin to form a crystallization solution; (2) incubating the crystallization solution for a time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1 mAb from the solution. In particular embodiments, the PEG is PEG 3350, and the additive is caffeine. The present invention also relates to novel anti-human PD-1 mAb crystals produced by the methods described herein. Characterization of the resolubilized crystal suspensions using several biochemical methods indicates that the biophysical properties of the resolubilized mAb crystals are consistent with the intact antibody starting sample. The crystals and methods of the present invention are suitable for a variety of pharmaceutical applications, such as purification, storage, formulation, and drug delivery.

The invention provides methods for producing crystalline an anti-PD-1 monoclonal antibody (mAb), wherein the mAb is pembrolizumab or a pembrolizumab variant, comprising (1) mixing a solution comprising (a) the mAb, (b) polyethylene glycol (PEG), and (c) an additive selected from the group consisting of: caffeine, theophylline, 2′ deoxyguanosine-5′-monophosphate, a bioactive gibberellin, and a pharmaceutically acceptable salt of said bioactive gibberellin, to form a crystallization solution, (2) incubating the crystallization solution for a period of time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1 mAb from the solution. In specific embodiments, the PEG is PEG 3350 and the additive is caffeine. The invention also relates to the novel anti-human PD-1 mAb crystals produced by the methods described herein. Characterization of re-dissolved crystalline suspensions using several biochemical methods showed the bio-physical properties of the re-dissolved mAb crystals were consistent with the intact antibody starting sample. The crystals and methods of the invention are amenable to multiple pharmaceutical applications such as purification, storage, formulation, and drug delivery.

The invention discloses a bacillus amyloliquefaciens riboswitch regulation and control system and application thereof. The regulation and control system is composed of a P43 promoter, a theophylline aptamer TC, RBS, RepA-tag and a required regulation and control gene. A theophylline ribose switch regulation element is integrated on the upstream of a bacillus amyloliquefaciens regulation gene, and the expression quantity of the gene is precisely regulated through theophylline induced expression. Furthermore, a theophylline ribose switch regulation element is integrated to the upstream of the genes hemX and mtnN to obtain the dual-regulation engineering bacterium HZ-B. Under induction of 2mM theophylline, the heme yield and the 5-adenosylmethionine (SAM) yield of the dual-regulation engineering bacterium HZ-B are remarkably increased and are respectively increased by 33.1 times and 0.5 times compared with those of an original strain HZ-12.

The present invention relates to the technical field of chemical process, in particular to the IPC C07D473 field, and more specifically, to a preparation process of caffeine with high yield and its application in cosmetics. The present invention prepares caffeine through six steps: the formation of dimethyl 4AU, the formation of dimethyl NAU, the formation of dimethyl FAU, the formation of theophylline sodium salt, methylation reaction, and the purification of caffeine. During the purification process of the present invention, high-purity caffeine can be obtained by centrifugation only once, and the liquid obtained after purification can also recover caffeine through operations such as decolorization and concentration. The recovered caffeine and product one can be jointly purified continuously, which can improve the yield of the final high-quality caffeine. The caffeine prepared by the present invention not only has high purity, but also has high yield, is white in color and has extremely low cytotoxicity. When applied in the field of cosmetics, it can improve the soothing, anti-wrinkle and anti-hair loss effects of cosmetics.

The application provides theophylline sustained-release tablets, a preparation method and application thereof, and belongs to the technical field of medicines.The theophylline sustained-release tablets comprise the following raw materials in parts by weight: theophylline derivatives or theophylline 90-110 parts;hydroxyethyl cellulose 10-20 parts;polyvinylpyrrolidone 1-2 parts;hexadecanol 3-5 parts;octadecanol 3-6 parts;talcum powder 0.2-0.6 parts;and magnesium stearate 0.2-0.6 parts.The preparation method is simple, the synthesis condition is mild, the yield is high, the theophylline derivatives have high selectivity, strong bronchodilating effect, quick effect, long maintenance time, small gastric irritation, slight cardiac side effect and good biological activities such as anti-tuberculosis, anti-convulsion and smooth muscle relaxation, and the theophylline derivatives are in a sustained-release dosage form, the drug action time is prolonged, and the theophylline derivatives have a wide application prospect.

The present invention provides a method for producing a crystalline anti-PD-1 monoclonal antibody (mAb) wherein the mAb is pembumab or a pembumab variant, the method comprising (1) mixing a solution comprising (a) mAb, (b) polyethylene glycol (PEG), and (c) an additive to form a crystalline solution, the additive is selected from caffeine, theophylline, 2 '-deoxyguanosine-5'-monophosphate, bioactive gibberellin and pharmaceutically acceptable salts of the bioactive gibberellin; (2) incubating the crystallization solution for a time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1mAb from the solution. In a particular embodiment, PEG is PEG 3350, and the additive is caffeine. The present invention also relates to novel anti-human PD-1mAb crystals produced by the methods described herein. Characterization of the redissolved crystal suspension using several biochemical methods shows that the biophysical properties of the redissolved mAb crystals coincide with the intact antibody starting sample. The crystals and methods of the present invention are suitable for a variety of pharmaceutical applications, such as purification, storage, formulation and drug delivery.

The present invention relates to a pharmaceutical composition comprising theophylline or a pharmaceutically acceptable salt thereof and thus capable of endothelial cell-dependent vasodilation.

The disclosure relates to a method for eliminating interference of theophylline in immunoassay and an immunodetection kit. The method for eliminating interference of theophylline in immunoassay includes: performing an immunoassay in the presence of a theophylline interference-resistant agent, the theophylline interference-resistant agent having a final concentration of 0.1 mg / mL-100 mg / mL, and being selected as at least one component from a group consisting of free 6-mercaptopurine, 6-thioguanine, 8-azguanine, hypoxanthine, adenine, purine, 2,6,8-trioxypurine, adenine nucleotide, and adenosine. The method and the kit can effectively reduce interference of theophylline on immunoassay results.

The invention belongs to the technical field of biology, and particularly relates to a genetically engineered bacterium and application of the genetically engineered bacterium in preparation of xylitol through a biological method. According to the invention, several expression control technologies such as theophylline switch, Cre / LoxP and the like are utilized, so that the expression products of the genetically engineered bacteria can be controlled by judging whether theophylline is added or not, the expression products are arabinose-1-dehydrogenase and then xylose reductase, after arabinose is consumed by the arabinose-1-dehydrogenase, xylose is converted into xylitol by utilizing the xylose reductase, and the xylose is converted into xylitol by utilizing the xylose reductase. The generation of byproducts in the process of preparing the xylitol from the hemicellulose hydrolysate is prevented.

Puerarin and theophylline co-crystal, preparation method thereof, and composition and use thereof. The present application discloses a co-crystal formed by combining puerarin (English name: Puerarin) and theophylline (English name: Theophylline) through non-covalent bonds, and a preparation method and use thereof. Specifically, the present application discloses a co-crystal formed by puerarin and theophylline, the molecular formula of the co-crystal is C 21 H 20 O9·C7H8N4O2; a preparation method of the puerarin and theophylline co-crystal; and application of the puerarin and theophylline co-crystal in preparation of a drug having effects of preventing and treating cardiovascular diseases, antioxidation, anticancer, antihypertension, blood sugar reduction, anti-inflammation, antipyretic analgesia, anti-Alzheimer's disease, anti-osteoporosis, cardiotonic, diuresis, coronary artery expansion, bronchial smooth muscle relaxation, and central nervous system excitation.